Alkem Laboratories Limited

ALKEM

INE540L01014

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:40:46 2024-04-29 am EDT			5-day change	1st Jan Change
4,884 ^INR	-0.55%		+2.90%	-6.13%

Apr. 16	Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak	CI
Mar. 28	Alkem Laboratories Forms Subsidiary for Medical Devices Business	MT

Alkem Subsidiary Enzene Launches Adalimumab Biosimilar In India

March 10, 2023 at 07:12 am EST

As reported by HealthCareRadius in India, on February 23, 2023, Enzene Biosciences, a subsidiary of Alkem Laboratories, announced commencement of commercial supplies of its biosimilar adalimumab (ENZ-129) in India to treat ankylosing spondylitis (AS) and rheumatoid arthritis (RA). This is Enzene's fourth biosimilar launch in the last eighteen months. In addition, this is the first commercial launch using its continuous manufacturing technology, which Enzene hopes will reduce the costs of AS and RA treatment for patients across India. According to Dr. Himanshu Gadgil, CEO at Enzene Biosciences, "[w]e have been working on this novel fully integrated platform for the last six years and the commercialization of adalimumab is a validation of our innovation-based work culture."

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Kristin M. Beale, Ph.D.
Goodwin Procter LLP
100 Northern Avenue
Boston
MA 02210
UNITED STATES
Tel: 212813 8800
E-mail: rmertz@goodwinlaw.com
URL: www.goodwinlaw.com

Latest news about Alkem Laboratories Limited

Alkem Laboratories Limited Receives A Demand Order Levying A Penalty of INR 35,099 State Tax Officer, Ghatak	Apr. 16	CI
Alkem Laboratories Forms Subsidiary for Medical Devices Business	Mar. 28	MT
Alkem Laboratories Limited Announces Incorporation of Subsidiary Alkem Medtech Private Limited	Mar. 28	CI
Alkem Laboratories Gets 10 Observations from US FDA After Baddi, India Unit Inspection	Mar. 27	MT
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	Feb. 12	MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR4,470 From INR3,960, Keeps at Underperform	Feb. 12	MT
Transcript : Alkem Laboratories Limited, Q3 2024 Earnings Call, Feb 09, 2024	Feb. 09
Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024	Feb. 09	CI
Alkem Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 09	CI
Indian Equities Close Higher on Friday, Lifted by IT Stocks	Jan. 12	MT
Alkem Laboratories Names Successor to Outgoing CFO	Jan. 12	MT
Alkem Laboratories Limited Announces CFO Changes	Jan. 12	CI
Heritage Global, Investors Acquire Pharmaceutical Plant from Alkem Laboratories	Jan. 11	MT
Federal Machinery & Equipment Co., Heritage Global Partners, Inc., New Mill Capital LLC, Keith Machinery Corp acquired Pharmaceutical Site in Fenton Missouri from Alkem Laboratories Limited.	Jan. 10	CI
Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023	Dec. 15	CI
Alkem Laboratories Limited Submits Clinical Trial Application to Central Drugs Standard Control Organization in India	Dec. 12	CI
Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy	Dec. 12	CI
Biosergen's Indian Partner Seeks Approval for Clinical Trial of Antifungal Drug Candidate	Dec. 12	MT
Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position	Dec. 05	CI
Alkem Laboratories Gets Three Observations from US FDA After Mandva, India Unit Inspection	Dec. 03	MT
Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position	Nov. 30	CI
Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director	Nov. 23	CI
Nomura Upgrades Alkem Laboratories to Buy From Neutral, Adjusts Price Target to INR4,963 From INR3,632	Nov. 09	MT
Jefferies Adjusts Alkem Laboratories’ Price Target to INR3,600 From INR3,550, Keeps at Underperform	Nov. 08	MT
Alkem Laboratories' Consolidated Profit Jumps in Fiscal Q2; Shares Climb 6%	Nov. 08	MT

Chart Alkem Laboratories Limited

Duration

Period

More charts

Company Profile

Alkem Laboratories Limited is an India-based company, which is engaged in the pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Companyâs product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The Company operates through a segment, Pharmaceuticals. It has approximately 21 manufacturing facilities at multiple locations in India and the United States. The Company has approximately 800 brands and operates in 40 countries.

Sector

Pharmaceuticals

Calendar

2024-05-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Alkem Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

4,910 INR

Average target price

5,184 INR

Spread / Average Target

+5.57%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ALKEM LABORATORIES LIMITED	-6.13%	7.04B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+26.51%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+14.87%	231B
NOVARTIS AG	+5.23%	200B
ROCHE HOLDING AG	-8.83%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals

Alkem Laboratories Limited

Equities

ALKEM

INE540L01014

Pharmaceuticals

Alkem Subsidiary Enzene Launches Adalimumab Biosimilar In India

EPS Revisions